A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

Abstract

Low-dose bevacizumab augmented by imatinib selects a mature, highly normalised and well perfused tumour vasculature without inducing incremental ECM deposition that normally limits the effectiveness of VEGF targeting drugs.